- This portfolio expansion is the result of an ongoing collaboration and license agreement between CEVEC and CellGenix for the development and GMP production of selected cytokines for ex vivo cell culture therapy applications using CEVEC’s proprietary CAP®Go technology
- CEVEC’s CAP®Go technology enables CellGenix access to new cytokines and proteins requiring human post-translational modifications not provided by bacterial expression systems
- CellGenix® recombinant human transforming growth factor-beta 1 (rh TGF-ß1) is used for the expansion of pluripotent stem cells (PSC) and mesenchymal stem cells (MSC) as well as for the differentiation of T cells into regulatory T cells (Treg cells) and the expansion of Treg cells
- CAP®Go-derived GMP TGF-ß1 is planned to become available in the second half of 2018
Cevec, Portfolio News
Go for quality: New Center for Biohybrid Medical Systems at RWTH Aachen University embarks on digital data management
Together with labfolder, the NRW Priority Professorship Biohybride and Medical Textiles in the new Center for Biohybrid Medical Systems at the RWTH Aachen University embarks on digital data management. Goals are the protection and traceability of the primary data, but the vision is to structure Big Data and also data that may have previously been ignored.
CEVEC to introduce new helper-free AAV packaging cell line for scalable stable gene therapy vector production at the Phacilitate Cell & Gene Therapy World Conference
- Newly developed helper-free AAV packaging cell line provides unique solution for large-scale viral gene therapy vector production
- Easy and stable production processes, independent of transient transfection or helper virus
- Data from CEVEC’s successful proof-of-concept studies will be presented at the conference
Miracor Medical raises € 25m
Funds will be used to support clinical and prepare commercial activities.
Company relocates from Austria to Belgium
Read more
CEVEC has been granted a new CAP®Go technology patent and reinforces its leading role in production of recombinant proteins previously out of reach
- New patent paves the way for further market expansion for CAP®Go expression platform
- Patent strengthens CEVEC’s unique position in producing recombinant proteins with tailor-made glycosylation
- Important milestone in establishing CAP®Go as the production standard for difficult-to- express recombinant glycoproteins
labfolder selected for the Merck Accelerator
The Berlin start-up company labfolder, which is developing an electronic lab notebook, was selected out of 475 applicants worldwide to participate in the Accelerator program of the science and technology company Merck in Darmstadt for three months, starting today.
labfolder Expands to North America and Initiates Collaboration with the German Accelerator Life Sciences
Digital lab notebook platform company opens office in Cambridge to support U.S. growth and customer Relations
BERLIN & CAMBRIDGE, Mass. labfolder and the German Accelerator Life Sciences (GALS), an initiative supported by the German Federal Ministry for Economic Affairs and Energy (BMWi), today announced the initiation of an extensive collaboration supporting the company’s expansion into the North American markets. With thousands of users and a growing number of customers in the U.S. already, the newly established Cambridge office will accelerate those efforts and support customer relations. Read more
Appointment of Bent Johnsen as CEO for EMPERRA®
Potsdam
EMPERRA®, specializing in digital health solutions for people living with diabetes, has appointed Mr. Bent Johnsen as Managing Director and CEO. Read more
Emperra Wins the 2017 Game Changers Award for Digital Business Models
Potsdam
Emperra GmbH, a start-up company based in Potsdam, Germany, has received the Finance Monthly’s 2017 Game Changers Award. The award is honouring Emperra for its new digital business models, which – based on innovative hardware – enable business revenue to be generated from digital solutions. The 2017 Game Changers Awards honour the innovation and strategic vision of a number of globally recognised specialists across a number of different industrial sectors. Read more
CEVEC and PlasmidFactory announce collaboration regarding adeno-associated virus (AAV) production
-
Parties intend to jointly enable AAV production in CEVEC’s CAP(R)GT cells in combination with PlasmidFactory’s broad AAV serotype plasmid portfolio
-
Collaboration will significantly increase the value of CAP(R)GT for CEVEC customers by broadening the spectrum of available adeno-associated viral (AAV) vectors for gene therapy applications
Humedics Announces Appointment of Karsten Damgaard-Iversen as CEO
Reinforcement of senior management team to leverage growth phase of Humedics
Berlin. The Board of Humedics GmbH is pleased to announce a reinforcement of the senior team of the company with Karsten Damgaard-Iversen (MBA, BScEE), who will take up the role of CEO as of June 1, 2017. Erwin de Buijzer will stay on as managing director (MD) with the title Chief Operations Officer (COO). Read more
The Berlin Institute of Health adopts the digital laboratory data management platform from the Berlin-based start-up labfolder
The Berlin-based start-up labfolder has won a second major client: beginning in April 2017, the Berlin Institute of Health (BIH) will be introducing labfolder’s electronic lab notebook as part of its quality initiative. The innovative data management software will be made available to more than 4,000 researchers at the Charité and the Max Delbrück Center for Molecular Medicine. Read more
CEVEC, medac and Provecs Medical enter into far-reaching adenoviral vector collaboration in oncology
-
Project will cover the entire process from R&D up to manufacturing and clinical development of adenoviral vectors for medac’s oncology products using CEVEC’s proprietary CAP(R)GT Technology
-
Collaboration is next step in setting CAP(R)GT as global standard in adenoviral gene therapy
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, Provecs Medical GmbH (Provecs), a biopharmaceutical company specialized in the development of cancer microenvironment immunotherapeutics based on adenoviral vector technology , and medac Gesellschaft fuer klinische Spezialpraeparate GmbH (medac), a pharmaceutical company specialized in the diagnosis and treatment of oncological, urological and autoimmune diseases, today announced that the companies have agreed on a broad collaboration for the research, development, manufacture and clinical development of adenoviral vectors for use in oncology indications. Read more
Biotech platform: Interview with CEVEC pharmaceuticals
The CSO of PVPs Portfolio Company CEVEC pharmaceuticals, Nicole Faust, was interviewed by labbiotech.eu – the leading digital media covering the European biotech industry – on CEVECS CAP Technology and it’s fight against the Zika Virus. Read more
CEVEC licenses CAP(R) technologies for the development and commercialization of vaccines against Zika Virus infections
Agreement marks an important step in establishing CAP(R) technologies as the new global industrial standard for viral vector and vaccine development
Cologne. CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that it has signed an exclusive license agreement with NewLink Genetics (NASDAQ:NLNK) for use of its proprietary CAP(R)GT and CAP(R)Go cell lines in the development and commercialization of products for the treatment and prophylaxis of Zika virus infections. Read more
Emperra Wins Prestigious Award With Innovative Diabetes Device
London. Emperra GmbH E-Health Technologies was announced Business Worldwide Magazine’s (BWM) 2016 Company of the Year Award/Medical Device Industry Europe for its innovative diabetes management system. Read more
LiMAx test enables better timing of liver surgery for colorectal liver metastatic patients after chemotherapy
Determination of liver function is crucial to assess patient’s eligibility for safe liver resection
Berlin. Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that two studies show the potential of the LiMAx test to better assess the eligibility of colorectal cancer patients for liver metastases resection after chemotherapy. The LiMAx test was used to explore the effects of oxaliplatin-based chemotherapy on liver function. Read more
CEVEC submits Biologics Master File (BB-MF) for CAP(R) Technology to the U.S. FDA
- Submission represents an important step towards establishing CAP(R)GT and CAP(R)Go technologies as the new industrial standards for viral vaccines, commercial-scale gene therapy vectors and recombinant protein production
- CEVEC’s CAP(R) technology licensees can reference BB-MF, simplifying and accelerating their regulatory approval process for a CAP(R)-derived product.
Labfolder signs Agreement with Max Planck Society for organization-wide use of laboratory data digital platform
- Contract provides up to 11,000 Max Planck scientists access to use labfolder for digital laboratory data Management
- First organization-wide digital laboratory data management deal for a Research institute across all disciplines globally
- Long-term collaboration between labfolder and the Max Planck Society to further develop the platform
- Digitalization of laboratory data management is a key driver in future scientific Innovation
Business Worldwide-Interview with CEO of PVPs Portfolio Company Emperra
Christian Krey, CEO of PVPs Portfolio Company Emperra, in interview with the Business Worldwide Magazine. Read more
CEVEC further strengthens organization to drive industrialization and commercialization of CAP(R) technologies
- Life sciences industry veteran Bart Bergstein to join CEVEC’s Supervisory Board
- Two newly formed Scientific Advisory Boards for CEVEC’s CAP(R)GT and CAP(R)Go technologies will further drive industrialization
CEVEC and Paragon Bioservices enter into comprehensive collaboration to roll out CAP(R) technologies in North America
- Agreement establishes Paragon as CEVEC’s preferred partner for contract development and manufacturing (CDMO) services in North America
- Companies will conduct coordinated marketing and business development activities to establish CEVEC’s CAP(R) technologies as a new standard for gene therapy vector production
- Collaboration includes developing a scalable clinical production process for AAV-based gene therapy vectors based on the CAP(R)GT platform
Humedics submists Marketing authorizaion application for the diagnostic agent with the LiMAx test
Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced that the company has submitted the marketing authorization application for the diagnostic agent necessary for the performance of the LiMAx test. The dossier was submitted in Germany, UK and Austria. Read more
CEVEC’s CAP®GT sets a new standard through RCA-free production of adenoviral vectors for gene therapy applications
- CAP®GT technology for fully scalable industrial adenoviral vector production with proven absence of replication-competent adenovirus (RCA)
- CAP®GT technology is underway to replace HEK293 as current production host for adenoviral vector
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company’s proprietary cell-expression system, CAP®GT, has delivered the production of safe adenoviral (AV) gene therapy vectors with the proven absence of RCAs. Read more
CEVEC intensifies its marketing activities, presenting at various renowned scientific conferences in Europe and the US
Cologne, Germany
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, today announced that the Company will present at the following renowned international scientific cell culture and gene therapy conferences in Europe and the US to promote the unique and superior features of its proprietary platform technologies CAP®Go and CAP®GT to industrial players in biopharmaceutical and gene therapy applications. Read more
CEVEC and Beckman Research Institute of City of Hope enter into a cooperation and license agreement on CEVEC’s proprietary CAP(R)GT technology
- CEVEC’s CAP(R)GT technology enables fully scalable lentiviral and RCA (replication competent adenovirus)-free adenoviral vector production
- Further step to establish CEVEC’s CAP(R)GT technology as the industrial standard for the production of lentiviral and adenoviral gene therapy vectors
Use of LiMAx test leads to reduction in post-hepatectomy liver failure and related mortality
Humedics GmbH, a specialist for real-time and mobile measurement of the individual liver function at the bedside of the patient, today announced results of a retrospective study investigating the impact of the LiMAx test on clinical patient outcome after hepatectomy. Study results showed that the use of the LiMAx test led to reductions in post-operative liver failure and to a decrease of liver failure related mortality. Read more
Emperra Digital Diabetes Care closes Series B round with Robert Bosch Venture Capital GmbH joining as a new investor
Emperra, a German start-up that has created a digital diabetes management solution consisting of smart hardware and software, has completed a Series B financing round of USD 3.1 million, with Robert Bosch Venture Capital GmbH (RBVC), a corporate venture capital company of the Bosch Group, joining the existing investors Peppermint VenturePartners and Investitionsbank des Landes Brandenburg. CEO Dr. Krey and CTO Dr. Schildt, management of Emperra, also participated in the round. The funds will be used for further product development and to accelerate international growth, predominantly in the United States and Europe. Read more
CEVEC and BioLamina combine technology leadership for commercial production of recombinant laminins for ex vivo cell therapies
- CEVEC adds laminins as CAP®Go application in the field of ex vivo cell culture products for cell therapies
- CEVEC’s CAP®Go to displace HEK293 and CHO cell lines in GMP manufacturing
- BioLamina to further grow its leading high quality ex vivo cell culture laminin product portfolio
- First commercial CAP®Go-derived laminin, LN-521, expected to be globally available in 2016
